Efficacy and safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss.
Phase of Trial: Phase III
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Brimapitide (Primary)
- Indications Sensorineural hearing loss
- Focus Registrational; Therapeutic Use
- Acronyms HEALOS
- Sponsors Auris Medical
- 28 Nov 2017 Top-line results presented in an Auris Medical media release.
- 28 Nov 2017 Primary endpoint (Pure tone average (PTA; average of the hearing threshold of three contiguous most affected hearing frequencies in dB)) has not been met according to an Auris Medical media release.
- 13 Oct 2017 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History